Targeting the Immune System to Improve Patient Outcomes in Advanced NSCLC
A CME-certified Oncology Exchange Program



Registration Statement


By clicking the Registration Button below you are agreeing that you have read and understood the CME Statements below.


Registration

  VenueCityStateDate
View Agenda  Pennsylvania Medical Society
Room Name: TBD
HarrisburgPA Friday
Sep 30, 2016 5:45 PM


Presentation Slides

Click here to view the presentation slides from this CME-certified series held at select ASCO®* state affiliate meetings. (coming soon)

*ASCO® is a registered trademark of the American Society of Clinical Oncology. These programs are not ASCO® events.

Program Description

The advent of targeted therapies significantly improved outcomes for patients with non-small cell lung cancer (NSCLC). However, those benefits are not uniform in all patients. There is a critical need to develop novel approaches that optimize patient outcomes. Immunotherapies have shown great promise in advanced NSCLC and could constitute a shift in clinical practice in the near future. Community oncologists must stay up to date with ongoing studies of immunotherapies and strategies to monitor response and immune-related adverse events in patients with advanced NSCLC.

Targeting the Immune System to Improve Patient Outcomes in Advanced NSCLC will provide guidance on the role of immunotherapy in patients with advanced NSCLC and explore molecular targets and mechanisms of action, clinical data for novel immunotherapies, strategies for monitoring and managing immune-related adverse events, and empowerment of patients to be active participants in treatment planning.

Agenda


Welcome and Introductions
Role of Immunotherapy in NSCLC
Clinical Case-based Discussions
         Case 1 – A patient with newly diagnosed PD-L1 positive metastatic NSCLC
         Case 2 – A patient with NSCLC whose disease has progressed beyond frontline therapy with platinum-based chemotherapy
Role of Biomarkers in Patient Selection for Immunotherapies
Q&A Session, Closing Remarks

Target Audience

This program is intended for oncologists, pathologists, pulmonologists, thoracic surgeons, intervention radiologists, nurses, and other health care professionals involved in the care of patients with NSCLC.


Educational Objectives

At the conclusion of this activity, participants should be able to demonstrate the ability to:
  • Evaluate mechanisms of action of immunotherapies in advanced NSCLC
  • Assess emerging data for immune checkpoint inhibitors in advanced NSCLC
  • Discuss the role of biomarkers in patient selection for immunotherapies
  • Educate patients with NSCLC about promising immunotherapeutic agents and clinical trial opportunities

Steering Committee


Suresh S. Ramalingam, MD
Professor of Hematology and Medical Oncology
Director, Division of Medical Oncology
Emory University
Winship Cancer Institute
Atlanta, GA

Read Biography 

John Powderly II, MD, CPI
President, Carolina BioOncology Institute PLLC
Adjunct Clinical Assistant Professor of Medicine
University of North Carolina School of Medicine
Duke University School of Medicine
Huntersville, NC

 Read Biography

Accreditation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

Designation Statement

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For questions regarding CME credit or the evaluation, please email contact@potomacme.org.

Disclosure Information

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.


FDA Disclosure

The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

Method of Participation

To complete the activity and receive credit, the participant must attend the program and complete the evaluation form. A CME certificate will be provided after submission of a completed evaluation form.

There is no fee associated with this program.

SPECIAL SERVICES

Event staff will be glad to assist you with any specials needs.  Please email specialservices@rockpointe-pcme.com at least 5 days prior to the program.


Jointly provided by the Potomac Center for Medical Education and Rockpointe Oncology

     
     

     

Supported by an independent educational grant from Genentech and Merck.

Registration Statement


By clicking the Registration Button below you are agreeing that you have read and understood the CME Statements above.

Registration is for planning purposes only. Seating is limited and will be provided on a first-come, first-served basis.



Registration

  VenueCityStateDate
View Agenda  Pennsylvania Medical Society
Room Name: TBD
HarrisburgPA Friday
Sep 30, 2016 5:45 PM